260 related articles for article (PubMed ID: 21716694)
1. Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass.
Portha B; Tourrel-Cuzin C; Movassat J
Exp Diabetes Res; 2011; 2011():376509. PubMed ID: 21716694
[TBL] [Abstract][Full Text] [Related]
2. beta-cell failure in diabetes and preservation by clinical treatment.
Wajchenberg BL
Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
[TBL] [Abstract][Full Text] [Related]
3. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.
Yamagishi S; Matsui T
Curr Pharm Des; 2011 Dec; 17(38):4379-85. PubMed ID: 22204436
[TBL] [Abstract][Full Text] [Related]
4. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.
Kirk RK; Pyke C; von Herrath MG; Hasselby JP; Pedersen L; Mortensen PG; Knudsen LB; Coppieters K
Diabetes Obes Metab; 2017 May; 19(5):705-712. PubMed ID: 28094469
[TBL] [Abstract][Full Text] [Related]
6. GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival.
Buteau J
Diabetes Metab; 2008 Feb; 34 Suppl 2():S73-7. PubMed ID: 18640589
[TBL] [Abstract][Full Text] [Related]
7. Liraglutide, a human glucagon-like peptide-1 analogue, stimulates AKT-dependent survival signalling and inhibits pancreatic β-cell apoptosis.
Kapodistria K; Tsilibary EP; Kotsopoulou E; Moustardas P; Kitsiou P
J Cell Mol Med; 2018 Jun; 22(6):2970-2980. PubMed ID: 29524296
[TBL] [Abstract][Full Text] [Related]
8. Activation of PPARβ/δ protects pancreatic β cells from palmitate-induced apoptosis by upregulating the expression of GLP-1 receptor.
Yang Y; Tong Y; Gong M; Lu Y; Wang C; Zhou M; Yang Q; Mao T; Tong N
Cell Signal; 2014 Feb; 26(2):268-78. PubMed ID: 24269940
[TBL] [Abstract][Full Text] [Related]
9. Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists.
Kielgast U; Holst JJ; Madsbad S
Curr Diabetes Rev; 2009 Nov; 5(4):266-75. PubMed ID: 19925391
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic approaches to preserve islet mass in type 2 diabetes.
Baggio LL; Drucker DJ
Annu Rev Med; 2006; 57():265-81. PubMed ID: 16409149
[TBL] [Abstract][Full Text] [Related]
11. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes.
Kang ZF; Deng Y; Zhou Y; Fan RR; Chan JC; Laybutt DR; Luzuriaga J; Xu G
Diabetologia; 2013 Feb; 56(2):423-33. PubMed ID: 23188390
[TBL] [Abstract][Full Text] [Related]
13. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
Henderson SJ; Konkar A; Hornigold DC; Trevaskis JL; Jackson R; Fritsch Fredin M; Jansson-Löfmark R; Naylor J; Rossi A; Bednarek MA; Bhagroo N; Salari H; Will S; Oldham S; Hansen G; Feigh M; Klein T; Grimsby J; Maguire S; Jermutus L; Rondinone CM; Coghlan MP
Diabetes Obes Metab; 2016 Dec; 18(12):1176-1190. PubMed ID: 27377054
[TBL] [Abstract][Full Text] [Related]
14. Specific actions of GLP-1 receptor agonists and DPP4 inhibitors for the treatment of pancreatic β-cell impairments in type 2 diabetes.
Dalle S; Burcelin R; Gourdy P
Cell Signal; 2013 Feb; 25(2):570-9. PubMed ID: 23159576
[TBL] [Abstract][Full Text] [Related]
15. Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice.
Wei R; Cui X; Feng J; Gu L; Lang S; Wei T; Yang J; Liu J; Le Y; Wang H; Yang K; Hong T
Metabolism; 2020 Oct; 111():154324. PubMed ID: 32712220
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-Like Peptide-1 Receptor Agonists: Beta-Cell Protection or Exhaustion?
van Raalte DH; Verchere CB
Trends Endocrinol Metab; 2016 Jul; 27(7):442-445. PubMed ID: 27160799
[TBL] [Abstract][Full Text] [Related]
17. Activation of GLP-1 and gastrin signalling induces in vivo reprogramming of pancreatic exocrine cells into beta cells in mice.
Sasaki S; Miyatsuka T; Matsuoka TA; Takahara M; Yamamoto Y; Yasuda T; Kaneto H; Fujitani Y; German MS; Akiyama H; Watada H; Shimomura I
Diabetologia; 2015 Nov; 58(11):2582-91. PubMed ID: 26290048
[TBL] [Abstract][Full Text] [Related]
18. Bioactive GLP-1 in gut, receptor expression in pancreas, and insulin response to GLP-1 in diabetes-prone rats.
Valverde I; Wang GS; Burghardt K; Kauri LM; Redondo A; Acitores A; Villanueva-Peñacarrillo ML; Courtois P; Sener A; Cancelas J; Malaisse WJ; Scott FW
Endocrine; 2004 Feb; 23(1):77-84. PubMed ID: 15034199
[TBL] [Abstract][Full Text] [Related]
19. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice.
Maida A; Lovshin JA; Baggio LL; Drucker DJ
Endocrinology; 2008 Nov; 149(11):5670-8. PubMed ID: 18669601
[TBL] [Abstract][Full Text] [Related]
20. Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits cell apoptosis induced by lipotoxicity in pancreatic β-cell line.
Wei Q; Sun YQ; Zhang J
Peptides; 2012 Sep; 37(1):18-24. PubMed ID: 22776329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
